CAPRICOR THERAPEUTICS, INC. (CAPR)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

7.83 on 9 Oct 2026

0 buys6 sales at will7 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$105.04M

Free cash flow

$72.72M

Return on equity

-34.4%

Return on capital

-27.9%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
25 Jun 2026	Bergmann Anthony CHIEF FINANCIAL OFFICER	Sold at will	$732.16K	68.2%
25 Jun 2026	Krasney Karen EVP, GENERAL COUNSEL	Sold at will	$732.16K	44.1%
24 Jun 2026	Bergmann Anthony CHIEF FINANCIAL OFFICER	Sold at will	$12.00K	3.4%
24 Jun 2026	Krasney Karen EVP, GENERAL COUNSEL	Sold at will	$12.00K	1.3%
22 Jun 2026	Krasney Karen EVP, GENERAL COUNSEL	Sold at will	$15.00K	1.6%
22 Jun 2026	Bergmann Anthony CHIEF FINANCIAL OFFICER	Sold at will	$15.00K	4.3%

26out of 100

Profitability 37

Financial strength 59

Growth 0

Insiders 0

Strongest on financial strength (59), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$8.37M

13 sales

Planned sales

54%

under a 10b5-1 plan